These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 30895619)

  • 1. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
    Zeng S; Liu S; Feng J; Gao J; Xue F
    Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
    Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
    Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
    Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
    J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
    Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
    Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
    Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
    Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
    Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
    Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
    EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
    Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
    Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
    Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
    J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
    Zhao H; Li N; Pang Y; Zhao J; Wu X
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
    Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
    Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
    Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
    Luo Y; Gui R
    J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
    Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
    Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.